Biogen has agreed to acquire RayThera Inc. for up to $1 billion, including upfront and milestone payments. This acquisition adds multiple anti-inflammatory drug candidates to Biogen's immunology portfolio, with the lead asset expected to enter Phase 1 clinical trials in Q3 2026. The deal aims to expand Biogen's presence in immune-mediated disease treatment and accelerate development of RayThera's pipeline. The transaction is expected to close in Q3 2026, pending regulatory approvals.

More News (BIIB)

Law firm investigates Biogen for possible securities fraud after Alzheimer's drug trial misses key goal.

Pomerantz LLP is investigating Biogen Inc. for potential securities fraud following the company's announcement that its Phase 2 trial for an Alzheimer's drug, diranersen, missed its primary endpoint despite being described as "compelling." The news c...

Market News

Bearish

1 day ago

Biogen to acquire RayThera for up to $1B, boosting immunology pipeline with new drug candidates.

More News (BIIB)

Law firm investigates Biogen for possible securities fraud after Alzheimer's drug trial misses key goal.

Invest & Trade with
#1 Award-Winning Investment Super App

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store

Biogen to acquire RayThera for up to $1B, boosting immunology pipeline with new drug candidates.

More News (BIIB)

Law firm investigates Biogen for possible securities fraud after Alzheimer's drug trial misses key goal.

Invest & Trade with#1 Award-Winning Investment Super App

iOS App Store

Google Play Store

Invest & Trade with
#1 Award-Winning Investment Super App